Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Di(Hydroxyethyl)Ether. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Di(Hydroxyethyl)Ether SCHEMBL10480450 | 1.00 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| SCHEMBL29137364 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| Hexaethylene Glycol SCHEMBL4379136 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| SCHEMBL28704841 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| Hexaethylene Glycol SCHEMBL11280667 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| SCHEMBL29249377 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| Tetraethylene Glycol SCHEMBL1145155 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| Triethylene Glycol SCHEMBL6130636 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| Tetraethylene Glycol SCHEMBL3062384 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| Pentaethylene Glycol SCHEMBL3466434 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930514-A | Isosteviol-based fluorescent probe and preparation method and application thereof | 南京工业大学 | 2025-05-06 | — | — | CN | claimed |
| CN-118290412-A | Glutamate dehydrogenase degradation agent and preparation method and application thereof | 杭州汉菁生物科技有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-119930514-A | Isosteviol-based fluorescent probe and preparation method and application thereof | 南京工业大学 | 2025-05-06 | — | — | CN | disclosed |
| CN-118290412-A | Glutamate dehydrogenase degradation agent and preparation method and application thereof | 杭州汉菁生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118063505-A | Unsaturated gemini Ji An acid ester and preparation method thereof | 江苏海洋大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-114716385-B | Compound of targeted focal adhesion kinase, preparation method and application | 北京师范大学 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023234415-A1 | COMPOSITE SEMIPERMEABLE MEMBRANE AND METHOD FOR PRODUCING SAME | 東レ株式会社 | 2023-12-07 | — | — | WO | disclosed |
| CN-116178258-B | N-methylaniline quinoline compound and synthetic method and application thereof | 中国医学科学院北京协和医院 | 2023-11-21 | — | — | CN | disclosed |
| CN-116239504-B | Isocyanate crosslinking agent containing double quaternary ammonium cations and polysulphonazole and preparation method thereof | 江苏海洋大学 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023193795-A1 | COMPOUND TARGETING FOCAL ADHESION KINASE AND PREPARATION METHOD FOR AND APPLICATION OF COMPOUND | 北京师范大学 | 2023-10-12 | — | — | WO | disclosed |
| CN-116640094-A | Compounds as PRMT1 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-7378203-B2 | Ferrocene(di)carboxaldehyde N-phenylhydrazone and monomeric, bridged or polymeric derivatives; good mechanical and electrostatic properties; can be used with liquid and dry toners to produce high quality images; imaging systems can be maintained after repeated cycling; electrography | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-05-27 | — | — | US | disclosed |
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| EP-1817310-A1 | (SPIROCYCLYLAMIDO) AMINOTHIOPHENE COMPOUNDS AS C-KIT PROTO-ONCOGENE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060210897-A1 | Charge transport materials having at least a metallocene group | S-PRINTING SOLUTION CO., LTD. (KR) | 2006-09-21 | — | — | US | disclosed |
| WO-2006034015-A1 | (SPIROCYCLYLAMIDO) AMINOTHIOPHENE COMPOUNDS AS C-KIT PROTO- ONCOGENE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063791-A1 | (Spirocyclylamido)aminothiophene compounds | OSI PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | disclosed |
| US-4728337-A | AFTERTREATMENT TO DYEING WITH ANIONIC DYES | CIBA-GEIGY CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| US-4721512-A | FINISHING LIQUID | CIBA-GEIGY CORPORATION (US) | 1988-01-26 | — | — | US | disclosed |
| US-4137080-A | POLYFUNCTIONAL COUPLER AND DEVELOPER | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | TPH1, NTSR1, HTR1D | ALDH1A1 254/4885SMN1; SMN2 2219/4885LMNA 1764/4885 |
| US-20060063791-A1 | (Spirocyclylamido)aminothiophene compounds | KIT, BRDT, MALT1 | ALDH1A1 488/4885SMN1; SMN2 1046/4885LMNA 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.